Regentis’ GelrinC Establishes Long-Term Durability of Cartilage Repair Through Quantitative MOCART Evaluation

Marks a world-first as Regentis uses MOCART, a quantitative standard to measure regeneration of cartilage in a clinical ...
Seeking Alpha

Evaxion reports 75% Objective Response Rate in phase 2 trial with AI-designed personalized cancer vaccine EVX-01

75% Objective Response Rate as 12 out of 16 advanced melanoma patients had objective clinical responses, with 11 of the 12 responders continuing to respond at 24 months follow-up Immune activation ...
NBC News

Contrast therapy is trending — but does it actually work?

Need relief from achy muscles? The most common treatment is either a heating pad or a cold pack. But, according to experts, you should be treating your sore muscles with both. Using hot and cold in ...
Frontiers

Magnetic resonance angiography for cerebral arterial and venous visualization in dogs: a comparative study of time-of-flight, phase-contrast, and time-resolved imaging of ...

1 Department of Veterinary Medical Imaging, College of Veterinary Medicine, Seoul National University, Seoul, Republic of Korea 2 NEL Animal Medical Center, Anyang-si, Republic of Korea This study ...
Frontiers

CSF flow measurement in the mesencephalic aqueduct using 2D cine phase-contrast MRI in dogs with communicating internal hydrocephalus, ventriculomegaly, and physiologic ...

Background: Brachycephalic dogs are overrepresented with ventricular enlargement. Cerebrospinal fluid (CSF) flow dynamics are not completely understood. MRI techniques have been used for the ...
IEEE

Multi-Objective MMF Reconstruction Design for Vibration Suppression in Modular Dual 3-Phase PMSM With Open-Phase Fault

Abstract: This paper proposes a multi-objective magnetomotive force (MMF) reconstruction design for vibration suppression of modular dual 3-phase permanent magnet synchronous motor (PMSM) with the ...
Business Wire

GE HealthCare Announces Phase I Results for a First-of-its-Kind Macrocyclic Manganese-Based MRI Contrast Agent

Results of the Phase I clinical trial, presented at the bi-annual Contrast Media Research symposium in Oslo, Norway, conclude that this novel macrocyclic manganese-based contrast agent was well ...